Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination

Molecular and Cellular Neuroscience

Volumn 21, Issue 2, 2002, Pages 223-238

  Rideout, Hardy J ^a   Stefanis, Leonidas ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CASPASE INHIBITOR; CELL CYCLE PROTEIN; DACTINOMYCIN; LACTACYSTIN; PROTEASOME INHIBITOR; PROTEIN CDC34; THIOFLAVINE; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN CELL; CELL COUNT; CELL INCLUSION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; EMBRYO; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; RAT;

ANIMALIA;

EID: 0036432029     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcne.2002.1173     Document Type: Article

References (74)

1. Alves-Rodrigues, A., Gregori, L., and Figueiredo-Pereira, M. E. (1998). Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci. 21: 516-520.
2. Ancolio, K., Alves da Costa, C., Ueda, K., and Checler, F. (2000). Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285: 79-82.
3. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M., and Bonini, N. M. (2002). Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295: 865-868.
4. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowski, J. Q., and Iwatsubo, T. (1998). Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152: 879-884.
5. Banerjee, A., Deshaies, R. J., and Chau, V. (1995). Characterization of a dominant negative mutant of the cell-cycle ubiquitin-conjugating enzyme Cdc34. J. Biol. Chem. 270: 26209-26215.
6. Bence, N. F., Sampat, R. M., and Kopito, R. R. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555.
7. Bennett, M. C., Bishop, J. F., Leng, Y., Chock, P. B., Chase, T. N., and Mouradian, M. M. (1999). Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274: 33855-33858.
8. + on the state of tubulin polymerisation in NGF-differentiated PC12 cells. J. Neurosci. Res. 56: 28-35.
9. Chain, D. G., Hegde, A. N., Yamamoto, N., Liu-Marsh, B., and Schwartz, J. H. (1995). Persistent activation of cAMP-dependent protein kinase by regulated proteolysis suggests a neuron-specific function of the ubiquitin system in Aplysia. J. Neurosci. 15: 7592-7603.
10. Chang, Y. C., Lee, Y. S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., Mitsui, Y., and Magae, J. (1998). Mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9: 79 -84.
11. Chung, K. K., Dawson, V. L., and Dawson, T. M. (2001a). The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24: S7-S14.
12. Chung, K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2001b). Parkin ubiquitinates the α-synuclein-interacting protein, synphillin-1: Implications for Lewy-body formation in Parkinson disease. Nat. Med. 7: 1144-1150.
13. Ciechanover, A. (1998). The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J. 17: 7151-7160.
14. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4: 1318-1320.
15. Cummings, C. J., Reinstein, E., Sun, Y., Antalffy, B., Jiang, Y., Ciechanover, A., Orr, H. T., Beaudet, A. L., and Zoghbi, H. Y. (1999). Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24: 879-892.
16. Fenteany, G., and Schreiber, S. (1998). Lactacystin, proteasome function, and cell fate. J. Biol. Chem. 273: 8545-8548.
17. Figueiredo-Pereira, M. E., Berg, K. A., and Wilk, S. (1994). A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J. Neurochem. 63, 1578-1581.
18. Fliegner, K. H., Kaplan, M. P., Wood, T. L., Pintar, J. E., and Liem, R. K. (1994). Expression of the gene for the neuronal intermediate filament protein alpha-internexin coincides with the onset of neuronal differentiation in the developing rat nervous system. J. Comp. Neurol. 342: 161-173.
19. Friedman, W. J., Ibanez, C. F., Hallbook, F., Persson, H., Cain, L. D., Dreyfus, C. F., and Black, I. B. (1993). Differential actions of neurotrophins in the locus coeruleus and basal forebrain. Exp. Neurol. 119: 71-78.
20. Friquet, B., Bulteau, A. L., Chondrogianni, N., and Petropoulos, I. (2000). Protein degradation by the proteasome and its implications in aging. Ann. N. Y. Acad. Sci. 908: 143-154.
21. Galloway, P. G., Grundke-Iqbal, I., Iqbal, K., and Perry, G. (1988). Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 47: 654-663.
22. Ghee, M., Fournier, A., and Mallet, J. (2000). Rat alpha-synuclein interacts with tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75: 2221-2224.
23. Giasson, B. I., and Mushynski, W. E. (1997). Developmentally regulated stabilization of neuronal intermediate filaments in rat cerebral cortex. Neurosci. Lett. 229: 77-80.
24. Goebl, M. G., Yochem, J., Jentsch, S., McGrath, J. P., Varshavsky, A., and Byers, B. (1988). The yeast cell cycle gene CDC34 encodes a ubiquitin-conjugating enzyme. Science 241: 1331-1335.
25. Goldman, J. E., Yen, S. H., Chiu, F. C., and Peress, N. S. (1983). Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 221: 1082-1084.
26. Hashimoto, M., Hsu, L. J., Sisk, A., Xia, Y., Takeda, A., Sundsmo, M., and Masliah, E. (1998). Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res. 799: 301-306.
27. Hicke, L. (2001). Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell. Biol. 2: 195-201.
28. Hsu, L. J., Mallory, M., Xia, Y., Veinbergs, I., Hashimoto, M., Yoshimoto, M., Thal, L. J., Saitoh, T., and Masliah, E. (1998). Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J. Neurochem. 71: 338-344.
29. Ii, K., Ito, H., Tanaka, K., and Hirano, A. (1997). Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56: 125-131.
30. Imai, Y., Soda, M., and Takahashi, R. (2000). Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 276: 35661-35664.
31. Ishikawa, A., and Takahashi, H. (1998). Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J. Neurol. 245: 4-9.
32. Iwatsubo, T., Yamaguchi, H., Fujimuro, M., Yokosawa, H., Ihara, Y., Trojanowski, J. Q., and Lee, V. M. (1996). Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am. J. Pathol. 148: 1517-1529.
33. Johnston, J. A., Ward, C. L., and Kopito, R. R. (1998). Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 143: 1883-1898.
34. Kaplan, M. P., Chin, S. S., Fliegner, K. H., and Liem, R. K. (1990). Alpha-internexin, a novel neuronal intermediate filament protein, precedes the low molecular weight neurofilament protein (NF-L) in the developing rat brain. J. Neurosci. 10: 2735-2748.
35. Keller, J. N., Huang, F. F., and Markesbery, W. R. (2000a). Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98: 149-156.
36. Keller, J. N., Hanni, K. B., and Markesbery, W. R. (2000b). Possible involvement of proteasome inhibition in aging: Implications for oxidative stress. Mech. Ageing Dev. 113: 61-70.
37. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J., Schols, L., and Riess, O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18: 106-108.
38. Kwak, S., Masaki, T., Ishiura, S., and Sugita, H. (1991). Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains. Neurosci. Lett. 128: 21-24.
39. Lee, H.-J., Shin, S. Y., Choi, C., Lee, Y. H., and Lee, S.-J. (2002). Formation and removal of α-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277: 5411-5417.
40. Lee, M., Hyun, D., Halliwell, B., and Jenner, P. (2001). Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76: 998-1009.
41. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., Dehejia, A., Lavedan, C., Gasser, T., Steinbach, P. J., Wilkinson, K. D., and Polymeropoulos, M. H. (1998). The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452.
42. Le Vine, H., III (1993). Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci. 2: 404-410.
43. Lesort, M., Tucholski, J., Miller, M. L., and Johnson, G. V. (2000). Tissue transglutaminase: A possible role in neurodegenerative diseases. Prog. Neurobiol. 61, 439-463.
44. Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L., and Di Monte, D. A. (2002). The herbicide paraquat causes upregulation and aggregation of alpha-synuclein in mice. J. Biol. Chem. 277: 1641-1644.
45. Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W., and Roytta, M. (2000). Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. (Berlin) 100: 285-290.
46. McLean, P. J., Kawamata, H., and Hyman, B. T. (2001). α-Synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104: 901-912.
47. McNaught, K. S., and Jenner, P. (2001). Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297: 191-194.
48. McNaught, K. S., Olanow, C. W., Halliwell, B., Isacson, O., and Jenner, P. (2001). Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2: 589-594.
49. Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J. M., Farer, M., and Wolozin, B. (2000). The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20: 6048-6054.
50. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. (1995). Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 631-632.
51. Park, D. S., Levine, B., Ferrari, G., and Greene, L. A. (1997). Cyclin-dependent kinase inhibitors and dominant negative cyclin-dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J. Neurosci. 17: 8975-8983.
52. Pasquini, L. A., Moreno, M. B., Adamo, A. M., Pasquini, J. M., and Soto, E. (2000). Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells. J. Neurosci. Res. 59: 601-611.
53. Paxinou, E., Chen, Q., Weisse, M., Giasson, B. I., Norris, E. H., Rueter, S. M., Trojanowski, J. Q., Lee, V. M. Y., and Ischiropoulos, H. (2001). Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21: 8053-8061.
54. Plon, S. E., Leppig, K. E., Do, H. N., and Groudine, M. (1993). Cloning of the human homolog of the CDC34 cell cycle gene by complementation in yeast. Proc. Natl. Acad. Sci. USA 90: 10484-10488.
55. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
56. Qiu, J. H., Asai, A., Chi, S., Saito, N., Hamada, H., and Kirino, T. (2000). Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J. Neurosci. 20: 259-265.
57. Rideout, H. J., Larsen, K. E., Sulzer, D., and Stefanis, L. (2001a). Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899-908.
58. Rideout, H. J., Park, D. S., and Stefanis, L. (2001b). Cdk activity is required for neuronal death, but not inclusion formation, following proteasomal inhibition. Neurology 56: A28.
59. Rideout, H. J., Zhang, E., Yeasmin, M., Gordon, R., Jabado, O., Park, D. S., and Stefanis, L. (2001c). Inhibitors of trypsin-like serine proteases prevent DNA damage-induced neuronal death by acting upstream of the mitochondrial checkpoint and of p53 induction. Neuroscience 107: 339-352.
60. Saudou, F., Finbeiner, S., Devy, D., and Greenberg, M. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66.
61. Sherman, M. Y., and Goldberg, A. L. (2001). Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 29: 15-32.
62. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., and Suzuki, T. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25: 302-305.
63. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., and Selkoe, D. J. (2001). Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 293: 263-269.
64. Sisodia, S. S. (1998). Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial? Cell 95: 1-4.
65. Souza, J. M., Giasson, B. I., Lee, V. M., and Ischiropoulos, H. (2000). Chaperone-like activity of synucleins. FEBS Lett. 474: 116-119.
66. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
67. Stefanis, L., Park, D. S., Friedman, W. J., and Greene, L. A. (1999). Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J. Neurosci. 19: 6235-6247.
68. Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D., and Greene, L. A. (2001). Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21: 9549-9560.
69. Swaminathan, S., Amerik, A. Y., and Hochstrasser, M. (1999). The Doa4 deubiquitinating enzyme is required for ubiquitin homeostasis in yeast. Mol. Biol. Cell 10: 2583-2594.
70. Tanaka, Y., Engelender, S., Igarashi, S., Rao, R. K., Wanner, T., Tanz, R. E., Sawa, A., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2001). Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10: 919-926.
71. Tofaris, G. K., Layfield, R., and Spillantini, M. G. (2001). α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509: 22-26.
72. Trojanowski, J. Q., Goedert, M., Iwatsubo, T., and Lee, V. M. (1998). Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5: 832-837.
73. Tu, P.-H., Raju, P., Robinson, K. A., Gurney, M. E., Trojanowski, J. Q., and Lee, V. M.-Y. (1996). Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc. Natl. Acad. Sci. USA 93: 3155-3160.
74. Wojcik, C., Schroeter, D., Wilk, S., Lamprecht, J., and Paweletz, N. (1996). Ubiquitin-mediated proteolysis centers in HeLa cells: Indication from studies of an inhibitor of the chymotrypsin-like activity of the proteasome. Eur. J. Cell Biol. 71: 311-318.